Polymorph Control in N-Hydroxy-Propenamide Crystallization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The challenge lies in understanding and controlling polymorphism in N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide, as different crystal modifications can affect its physicochemical properties, solubility, and stability, leading to potential toxicity and production downtime if unintended polymorphs form during drug manufacture.
Innovation Solution
The development of specific crystalline forms, such as forms A, B, C, HA, and HB of the free base and their corresponding salts, which are characterized by x-ray powder diffraction patterns and produced through controlled solvent systems and crystallization conditions, ensuring reproducibility and high purity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional crystallization methods are used without controlled solvent systems and crystallization conditions, then the production process is simple and fast, but unintended polymorphs form causing toxicity and production downtime
Solution Approach 1:
The patent applies parameter changes by systematically varying solvent types, solvent ratios, temperature profiles, and crystallization times to selectively obtain desired polymorphs. Specific parameter combinations (e.g., ethanol/water ratio, temperature ramp rates) are optimized to favor particular crystal forms, thereby controlling polymorphism while maintaining a manageable process complexity
Solution Approach 2:
The patent employs preliminary action by pre-determining optimal crystallization conditions through screening studies before actual production. Polymorph selection is decided in advance based on predicted properties, and crystallization protocols are predetermined to ensure consistent formation of the desired polymorph, preventing unintended forms from arising during manufacture
2Manufacturing precision
If multiple polymorphic forms are produced without controlled conditions, then the production process is flexible, but the purity and consistency of the product deteriorates leading to potential toxicity
Solution Approach 1:
The patent applies local quality by optimizing specific local conditions within the crystallization system - such as local temperature gradients, localized solvent concentration zones, and specific pH ranges - to promote formation of particular polymorphs. By controlling these localized parameters, high purity polymorphs are obtained while the overall manufacturing process remains relatively simple
3Productivity
If unintended polymorphs form during manufacture, then the production process is robust, but production downtime increases while scientists search for and correct the cause
Solution Approach 1:
The patent implements feedback by incorporating real-time monitoring of crystallization processes and immediate adjustment of parameters based on observed outcomes. Polymorph formation is monitored through techniques like X-ray diffraction, and crystallization conditions are adjusted on-the-fly to prevent formation of unwanted polymorphs, eliminating the need for lengthy post-production investigations and downtime
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the reproducible preparation of stable, pure crystalline forms of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide, minimizing toxicity risks and production disruptions by controlling the crystallization process.
Implementation Method 1
characterized by x-ray powder diffraction patterns
Implementation Method 2
different crystal modifications (novel polymorphic forms of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide)
Implementation Method 3
produced through controlled solvent systems and crystallization conditions
Data Source
AI summary
Polymorphic forms of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide free base and salts thereof are prepared by various processes.